REZOLUTE INC. - COMMON STOCK (NV)

Rezolute to Participate in Upcoming Investor Conferences

01 May 2025 08:00:00 By Nasdaq GlobeNewswire

Rezolute, Inc. Announces Closing of Underwritten Offering

25 Apr 2025 16:30:35 By Nasdaq GlobeNewswire

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

23 Apr 2025 08:05:00 By Nasdaq GlobeNewswire

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

23 Apr 2025 08:00:01 By Nasdaq GlobeNewswire

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

26 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

12 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

04 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

31 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

07 Jan 2025 08:00:01 By Nasdaq GlobeNewswire

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

05 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

03 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

19 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in Upcoming Investor Conferences

27 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

05 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

31 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

24 Jun 2024 08:00:00 By Nasdaq GlobeNewswire